DK1417349T3 - Nyt molekulært mål for neurotoxicitet - Google Patents

Nyt molekulært mål for neurotoxicitet

Info

Publication number
DK1417349T3
DK1417349T3 DK02777405T DK02777405T DK1417349T3 DK 1417349 T3 DK1417349 T3 DK 1417349T3 DK 02777405 T DK02777405 T DK 02777405T DK 02777405 T DK02777405 T DK 02777405T DK 1417349 T3 DK1417349 T3 DK 1417349T3
Authority
DK
Denmark
Prior art keywords
pde4b
activity
expression
pde4
sequence
Prior art date
Application number
DK02777405T
Other languages
English (en)
Inventor
Ikhlef Ali Ait
Annelies Resink
Fabien Schweighoffer
Original Assignee
Exonhit Therapeutics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8866536&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1417349(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Exonhit Therapeutics Sa filed Critical Exonhit Therapeutics Sa
Application granted granted Critical
Publication of DK1417349T3 publication Critical patent/DK1417349T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pathology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
DK02777405T 2001-08-14 2002-08-13 Nyt molekulært mål for neurotoxicitet DK1417349T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0110819A FR2828693B1 (fr) 2001-08-14 2001-08-14 Nouvelle cible moleculaire de la neurotoxicite
PCT/FR2002/002861 WO2003016563A2 (fr) 2001-08-14 2002-08-13 Cible moleculaire de la neurotoxicite

Publications (1)

Publication Number Publication Date
DK1417349T3 true DK1417349T3 (da) 2009-03-23

Family

ID=8866536

Family Applications (2)

Application Number Title Priority Date Filing Date
DK02777405T DK1417349T3 (da) 2001-08-14 2002-08-13 Nyt molekulært mål for neurotoxicitet
DK08160783.0T DK1982704T3 (da) 2001-08-14 2002-08-13 Nyt molekylært mål for neurotoksicitet

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK08160783.0T DK1982704T3 (da) 2001-08-14 2002-08-13 Nyt molekylært mål for neurotoksicitet

Country Status (15)

Country Link
US (1) US6855736B2 (da)
EP (2) EP1417349B1 (da)
JP (1) JP4527395B2 (da)
CN (2) CN1541278A (da)
AT (2) ATE476530T1 (da)
AU (1) AU2002339017B2 (da)
CA (1) CA2457611C (da)
DE (2) DE60229953D1 (da)
DK (2) DK1417349T3 (da)
ES (2) ES2316625T3 (da)
FR (1) FR2828693B1 (da)
IL (2) IL160141A0 (da)
NZ (1) NZ530939A (da)
PT (2) PT1982704E (da)
WO (1) WO2003016563A2 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040219552A1 (en) * 2001-08-14 2004-11-04 Ali Ait Ikhlef Novel molecular target for neurotoxicity
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
AU2003283303A1 (en) * 2002-11-08 2004-06-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4b (pde4b)
FR2851247B1 (fr) * 2003-02-19 2007-06-29 Exonhit Therapeutics Sa Methodes et compositions pour le traitement de pathologies degeneratives oculaires
PT1477166E (pt) * 2003-04-28 2006-12-29 Biofrontera Bioscience Gmbh Utilização de riluzole combinado com substâncias auxiliares e aditivos adequados, para o tratamento de doenças caracterizadas por uma hiperproliferação de queratinócitos, especialmente de neurodermite e psoríase
FR2856595B1 (fr) * 2003-06-27 2008-05-30 Exonhit Therapeutics Sa Methodes et compositions pour le traitement de deficits cognitifs.
US20050079548A1 (en) * 2003-07-07 2005-04-14 Plexxikon, Inc. Ligand development using PDE4B crystal structures
EP1538218A1 (en) * 2003-12-04 2005-06-08 Erasmus University Medical Center Rotterdam Method to diagnose or screen for inflammatory diseases
WO2005058892A1 (en) * 2003-12-19 2005-06-30 Glaxo Group Limited Pyrazolo [3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors
CA2559629A1 (en) 2004-03-16 2005-09-29 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compound, and its use as a pde4 inhibitor
US7585859B2 (en) * 2004-05-06 2009-09-08 Plexxikon, Inc. PDE4B inhibitors and uses therefor
CN101048407A (zh) * 2004-09-03 2007-10-03 普莱希科公司 双环杂芳基pde4b抑制剂
WO2007071437A2 (en) * 2005-12-22 2007-06-28 Ares Trading S.A. Compositions and methods for treating inflammatory disorders
ES2353093B1 (es) * 2009-05-20 2012-01-03 Consejo Superior De Investigaciones Científicas (Csic) Uso de derivados de quinazolinas y sus composiciones farmacéuticas en enfermedades neurodegenerativas.
US20150079623A1 (en) * 2012-03-18 2015-03-19 Kyushu University, National University Corporation Apparatus, system and method for analyzing disease sample
CN105121439A (zh) 2013-02-19 2015-12-02 辉瑞公司 作为pde4亚型抑制剂用于治疗cns和其他病症的氮杂苯并咪唑化合物
WO2016012896A1 (en) 2014-07-24 2016-01-28 Pfizer Inc. Pyrazolopyrimidine compounds
HUE044040T2 (hu) 2014-08-06 2019-09-30 Pfizer Imidazopiridazin vegyületek

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977305A (en) * 1990-04-20 1999-11-02 Cold Spring Harbor Laboratories Cloning by complementation and related processes
US5672622A (en) † 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis
US6060501A (en) * 1994-06-02 2000-05-09 Schering Aktiengesellschaft Combined treatment of multiple sclerosis
JPH09509851A (ja) * 1994-12-23 1997-10-07 セルテック セラピューティックス リミテッド ヒトホスホジエステラーゼ型ｉｖｃ、並びにその生産および使用
FR2775984B1 (fr) 1998-03-11 2006-09-15 Bioscreen Therapeutics Sa Criblage differentiel qualitatif
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
CA2357950C (en) * 1998-12-30 2013-07-23 Oligo Therapeutics Inc. Therapeutic phosphodiesterase inhibitors
US6334998B1 (en) * 1999-12-07 2002-01-01 Parker Hughes Institute Estrogens for treating ALS
AU2433001A (en) * 1999-12-14 2001-06-25 University Of Utah Research Foundation Two novel camp-specific phosphodiesterase (pde4b) isoforms and related technology
CA2404858A1 (en) † 2000-04-12 2001-10-25 Minerva Biotechnologies Corporation Treatment of neurodegenerative disease
JP2002020386A (ja) † 2000-07-07 2002-01-23 Ono Pharmaceut Co Ltd ピラゾロピリジン誘導体
FR2856595B1 (fr) † 2003-06-27 2008-05-30 Exonhit Therapeutics Sa Methodes et compositions pour le traitement de deficits cognitifs.

Also Published As

Publication number Publication date
US6855736B2 (en) 2005-02-15
JP2005500066A (ja) 2005-01-06
JP4527395B2 (ja) 2010-08-18
EP1417349A2 (fr) 2004-05-12
DE60229953D1 (de) 2009-01-02
EP1982704B2 (fr) 2013-07-24
ATE476530T1 (de) 2010-08-15
PT1417349E (pt) 2009-02-09
WO2003016563A2 (fr) 2003-02-27
US20030064374A1 (en) 2003-04-03
EP1417349B1 (fr) 2008-11-19
IL160141A (en) 2010-12-30
EP1982704A2 (fr) 2008-10-22
WO2003016563A3 (fr) 2004-04-01
NZ530939A (en) 2006-11-30
ES2348348T3 (es) 2010-12-03
FR2828693B1 (fr) 2004-06-18
EP1982704B1 (fr) 2010-08-04
AU2002339017B2 (en) 2007-11-01
FR2828693A1 (fr) 2003-02-21
CN101632663A (zh) 2010-01-27
DE60237248D1 (de) 2010-09-16
ATE414790T1 (de) 2008-12-15
PT1982704E (pt) 2010-10-11
ES2348348T5 (es) 2013-12-04
CN101632663B (zh) 2011-11-30
CA2457611A1 (fr) 2003-02-27
DK1982704T3 (da) 2010-10-04
CA2457611C (fr) 2013-04-02
EP1982704A3 (fr) 2008-12-17
CN1541278A (zh) 2004-10-27
IL160141A0 (en) 2004-06-20
ES2316625T3 (es) 2009-04-16

Similar Documents

Publication Publication Date Title
DK1417349T3 (da) Nyt molekulært mål for neurotoxicitet
WO2001078711A3 (en) Pde-v inhibitors for treatment of parkinson's disease
MA27608A1 (fr) Derives d'hydroxyethylamine utilises pour le traitement de la maladie d'alzheimer
CY1112932T1 (el) Αναστολεις sμαd7 για τη θεραπευτικη αγωγη ασθενειων του κνς
NO20030895D0 (no) Ny anvendelse av dipeptidyl peptidase IV inhibitorer
MY134783A (en) Rho-kinase inhibitors
MY142915A (en) Rho-kinase inhibitors
MA28241A1 (fr) Derives d'indole hydroxyethylamine tricycliques et leur utilisation dans le traitement de la maladie d'alzheimer
HK1086011A1 (en) Ccr1 antagonists for the treatment of i.a demyelinating inflammatory disease
MXPA05009535A (es) Compuestos de acido n - alquil - hidroxamico - isoindolilo y sus usos farmaceuticos.
AP1459A (en) Hexahydrofuro [2,3-b] furan-3- YL-N-{3-[(1,3- benzodioxol-5- ylsufonyl) (isobutyl) amino]-1-benzyl-2-hydroxypropyl} carbamate as retroviral protease inhibitor.
EA200801711A1 (ru) Пролекарства возбуждающих аминокислот
MA28562B1 (fr) 1,3,4-oxadiazol-2-ones comme modulateurs de ppar delta et leur utilisation
PT1696905E (pt) 2-aminotetralinas substituídas para o tratamento preventivo da doença de parkinson
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
ATE448785T1 (de) Behandlung von entzündlicher darmerkrankung
MA27638A1 (fr) Utilisation de derives de carbamazepine dans le traitement de l'agitation chez des patients atteints de demence
ATE399758T1 (de) Derivate von 1-phenylalkancarbonsäuren zur behandlung von neurodegenerativen krankheiten
DE60211746D1 (de) Aminosäurederivate zur behandlung der alzheimer-krankheit
PT1255734E (pt) Derivados de isatina com actividade neurotrofica
NO20033541L (no) Anvendelse av fosfodiesteraseinhibitorer av type 4 ved hjertemuskelsykdommer
BR9906719A (pt) "n-óxidos de compostos heterocìclicos com atividade inibidora de tnf e de pde-iv"
DE69928814D1 (de) Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten
WO2004038405A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 43 (gpr43)
WO2004038421A3 (en) Diagnostics and therapeutics for diseases associated with human g protein-coupled receptor 41 (gpr41)